Cargando…

Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease

BACKGROUND: In this study, we examined the relative usefulness of serum copeptin levels as a surrogate marker of vasopressin (AVP) in adult polycystic kidney disease (ADPKD) by correlating it with baseline and longitudinal changes in markers of both renal function and common CVD manifestations (hype...

Descripción completa

Detalles Bibliográficos
Autores principales: Kocyigit, Ismail, Yilmaz, Mahmut Ilker, Gungor, Ozkan, Eroglu, Eray, Unal, Aydin, Orscelik, Ozcan, Tokgoz, Bulent, Sipahioglu, Murat, Sen, Ahmet, Carrero, Juan Jesús, Oymak, Oktay, Axelsson, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129193/
https://www.ncbi.nlm.nih.gov/pubmed/27899079
http://dx.doi.org/10.1186/s12882-016-0406-4
_version_ 1782470543775105024
author Kocyigit, Ismail
Yilmaz, Mahmut Ilker
Gungor, Ozkan
Eroglu, Eray
Unal, Aydin
Orscelik, Ozcan
Tokgoz, Bulent
Sipahioglu, Murat
Sen, Ahmet
Carrero, Juan Jesús
Oymak, Oktay
Axelsson, Jonas
author_facet Kocyigit, Ismail
Yilmaz, Mahmut Ilker
Gungor, Ozkan
Eroglu, Eray
Unal, Aydin
Orscelik, Ozcan
Tokgoz, Bulent
Sipahioglu, Murat
Sen, Ahmet
Carrero, Juan Jesús
Oymak, Oktay
Axelsson, Jonas
author_sort Kocyigit, Ismail
collection PubMed
description BACKGROUND: In this study, we examined the relative usefulness of serum copeptin levels as a surrogate marker of vasopressin (AVP) in adult polycystic kidney disease (ADPKD) by correlating it with baseline and longitudinal changes in markers of both renal function and common CVD manifestations (hypertensive vascular disease, atherosclerosis and endothelial dysfunction) that accompany the progression of this disease. METHODS: We studied a cohort of young and otherwise healthy ADPKD patients (n = 235) and measured cardiovascular function using flow-mediation dilatation (FMD), carotid intima media thickness (cIMT) and pulse wave velocity (PWV), as well as serum copeptin (commercial ELISA, a stable marker of AVP activity). The same analyses were carried out at baseline and after 3 years of follow-up. RESULTS: At baseline, median eGFR was 69 mL/min./1.73 m(2), mean FMD 6.9 ± 0.9%, cIMT 0.7 ± 0.1 mm, and PWV 8.1 ± 1.2 m/s. At follow-up, equivalent values were 65 (44–75) mL/min./1.73 m(2), 5.8 ± 0.9%, 0.8 ± 0.1 mm. and 8.2 ± 1.3 m/s. with all changes statistically significant. Plasma copeptin also rose from 0.62 ± 0.12 to 0.94 ± 0.19 ng/mL and this change correlated with ΔeGFR (-0.33, p < 0.001), ΔFMD (0.599, p < 0.001), ΔcIMT (0.562, p < 0.001) and ΔPWV (0.27, p < 0.001) also after linear regression modeling to correct for confounders. Finally, ROC analysis was done for a high baseline copeptin with ΔeGFR [cut-off:≤59], ΔFMD [cut-off: ≤7.08], ΔcIMT [cut-off:>0.76], and ΔPWV [cut-off:≤7.80]. CONCLUSIONS: Vascular dysfunction as reflected by FMD and cIMT, but not PWV or an altered cardiac geometry, precede most other signs of disease in ADPKD but is predicted by elevated levels of the circulating AVP-marker copeptin.
format Online
Article
Text
id pubmed-5129193
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51291932016-12-12 Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease Kocyigit, Ismail Yilmaz, Mahmut Ilker Gungor, Ozkan Eroglu, Eray Unal, Aydin Orscelik, Ozcan Tokgoz, Bulent Sipahioglu, Murat Sen, Ahmet Carrero, Juan Jesús Oymak, Oktay Axelsson, Jonas BMC Nephrol Research Article BACKGROUND: In this study, we examined the relative usefulness of serum copeptin levels as a surrogate marker of vasopressin (AVP) in adult polycystic kidney disease (ADPKD) by correlating it with baseline and longitudinal changes in markers of both renal function and common CVD manifestations (hypertensive vascular disease, atherosclerosis and endothelial dysfunction) that accompany the progression of this disease. METHODS: We studied a cohort of young and otherwise healthy ADPKD patients (n = 235) and measured cardiovascular function using flow-mediation dilatation (FMD), carotid intima media thickness (cIMT) and pulse wave velocity (PWV), as well as serum copeptin (commercial ELISA, a stable marker of AVP activity). The same analyses were carried out at baseline and after 3 years of follow-up. RESULTS: At baseline, median eGFR was 69 mL/min./1.73 m(2), mean FMD 6.9 ± 0.9%, cIMT 0.7 ± 0.1 mm, and PWV 8.1 ± 1.2 m/s. At follow-up, equivalent values were 65 (44–75) mL/min./1.73 m(2), 5.8 ± 0.9%, 0.8 ± 0.1 mm. and 8.2 ± 1.3 m/s. with all changes statistically significant. Plasma copeptin also rose from 0.62 ± 0.12 to 0.94 ± 0.19 ng/mL and this change correlated with ΔeGFR (-0.33, p < 0.001), ΔFMD (0.599, p < 0.001), ΔcIMT (0.562, p < 0.001) and ΔPWV (0.27, p < 0.001) also after linear regression modeling to correct for confounders. Finally, ROC analysis was done for a high baseline copeptin with ΔeGFR [cut-off:≤59], ΔFMD [cut-off: ≤7.08], ΔcIMT [cut-off:>0.76], and ΔPWV [cut-off:≤7.80]. CONCLUSIONS: Vascular dysfunction as reflected by FMD and cIMT, but not PWV or an altered cardiac geometry, precede most other signs of disease in ADPKD but is predicted by elevated levels of the circulating AVP-marker copeptin. BioMed Central 2016-11-30 /pmc/articles/PMC5129193/ /pubmed/27899079 http://dx.doi.org/10.1186/s12882-016-0406-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kocyigit, Ismail
Yilmaz, Mahmut Ilker
Gungor, Ozkan
Eroglu, Eray
Unal, Aydin
Orscelik, Ozcan
Tokgoz, Bulent
Sipahioglu, Murat
Sen, Ahmet
Carrero, Juan Jesús
Oymak, Oktay
Axelsson, Jonas
Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease
title Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease
title_full Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease
title_fullStr Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease
title_full_unstemmed Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease
title_short Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease
title_sort vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129193/
https://www.ncbi.nlm.nih.gov/pubmed/27899079
http://dx.doi.org/10.1186/s12882-016-0406-4
work_keys_str_mv AT kocyigitismail vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT yilmazmahmutilker vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT gungorozkan vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT eroglueray vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT unalaydin vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT orscelikozcan vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT tokgozbulent vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT sipahioglumurat vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT senahmet vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT carrerojuanjesus vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT oymakoktay vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease
AT axelssonjonas vasopressinrelatedcopeptinisanovelpredictorofearlyendothelialdysfunctioninpatientswithadultpolycystickidneydisease